ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 8 pooled it
32.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 8 syntheses or guidelines pooled it, 230 citations in OpenAlex.
- The role of stereotactic radiosurgery for prostate cancer spine metastasis - impact on hormone sensitivity and treatment outcomes: a systematic review of literature.Neurosurgical review · 2026Pooled it
- Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials.Radiation oncology (London, England) · 2026Pooled it
- Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.The Lancet. Oncology · 2026Pooled it
- Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.Frontiers in medicine · 2026Pooled it
- Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Pooled it
- Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials.Radiation oncology (London, England) · 2024Pooled it
- Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review).International journal of molecular sciences · 2023Pooled it
- Ablative radiotherapy in castration-resistant prostate cancer.BJU international · 2026Trial
- Dosimetry Analysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.BMC cancer · 2026Trial
- Trial
- Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).Prostate cancer and prostatic diseases · 2025Trial
- Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.European urology · 2025Trial
- Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial.International journal of radiation oncology, biology, physics · 2025Trial
- PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.Medical oncology (Northwood, London, England) · 2023Trial
- Trial
- Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.JAMA oncology · 2023Trial
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 16 institutions in 4 countries.
Matthew P DeekDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.ORCID 0000-0002-5949-5058
Kim Van der EeckenDepartment of Pathology and Human Structure and Repair, University of Ghent, Ghent, Belgium.
Philip SuteraDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-4021-5909
Rebecca A DeekDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Valérie FonteyneDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Adrianna A MendesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Karel DecaesteckerDepartment of Urology, Ghent University Hospital, Ghent, Belgium.
Ana Ponce KiessDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Nicolaas LumenDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Ryan PhillipsDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4895-9838
Aurélie De BruyckerDepartment of Urology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-3583-481X
Mark MishraDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.
Zaker RanaDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0002-3409-2965
Jason MolitorisDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0002-8221-1631
Bieke LambertDepartment of Radiology and Nuclear Medicine, Ghent University, and Department of Nuclear Medicine, AZ Maria-Middelares Ghent, Belgium.
Louke DelrueDepartment of Radiology, Ghent University Hospital, Ghent, Belgium.
Hailun WangDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0001-8651-2856
Kathryn LoweDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Sofie VerbekeDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-5402-8581
Jo Van DorpeDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-8175-2930
Renée BultijnckDepartment of Urology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-4122-2323
Geert VilleirsDepartment of Radiology and Nuclear Medicine, Ghent University, and Department of Nuclear Medicine, AZ Maria-Middelares Ghent, Belgium.ORCID 0000-0002-9073-3341
Kathia De ManDepartment of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
Filip AmeyeDepartment of Urology, AZ Maria-Middelares Ghent, Ghent, Belgium.
Daniel Y SongDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Theodore DeWeeseDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Channing J PallerDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-3658-1858
Felix Y FengDepartments of Medicine, Urology and Radiation Oncology, UCSF, San Francisco, CA.ORCID 0000-0002-0963-7687
Alexander WyattDepartment of Urologic Sciences, University of British Columbia, and Vancouver Prostate Centre, Vancouver, Canada.ORCID 0000-0003-2399-0329
Kenneth J PientaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-4138-2186
Maximillian DiehnDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-2032-0581
Soren M BentzenDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0002-7444-7564
Steven JoniauDepartment of Urology, Catholic University Leuven, Leuven, Belgium.ORCID 0000-0003-3195-9890
Friedl VanhaverbekeDepartment of Urology, AZ Nikolaas, Sint-Niklaas, Belgium.
Gert De MeerleerDepartment of Radiation Oncology, Catholic University Leuven, Leuven, Belgium.
Emmanuel S AntonarakisDepartment of Medicine, University of Minnesota School of Medicine, Minneapolis, MN.ORCID 0000-0003-0031-9655
Tamara L LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Alejandro BerlinDepartment of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Canada.ORCID 0000-0002-1880-6905
Shankar SivaDepartment of Radiation Oncology, Peter MacCallum Cancer Center, Melbourne Australia.ORCID 0000-0003-2840-0658
Piet OstDepartment of Radiation Oncology, Iridium Network, Antwerp, Belgium.ORCID 0000-0002-2203-4848
Phuoc T TranDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-0147-0376
Johns Hopkins University · USGhent University Hospital · BEUniversity of Maryland, Baltimore · USGhent University · BEKU Leuven · BEAZ Maria Middelares · BEMayo Clinic in Arizona · USPeter MacCallum Cancer Centre · AUPrincess Margaret Cancer Centre · CARutgers, The State University of New Jersey · USStanford University · USUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Minnesota · USUniversity of Pennsylvania · USVlaamse Vereniging voor Obstetrie en Gynaecolo · BE
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MResource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Phuoc T. Tran · 2022 to 2026
$8.9MTumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9MIntegrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2MOpportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6MNCI NIH HHS P30 CA006973NCI NIH HHS T32 CA193145NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776NCI NIH HHS U54 CA273956
Abstract
PubMed holds no abstract for this paper.
Indexed as
Prostatic NeoplasmsClinical Trials as TopicHumansMaleProgression-Free SurvivalTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.